2014年3月
Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript
EUROPEAN JOURNAL OF HAEMATOLOGY
- 巻
- 92
- 号
- 3
- 開始ページ
- 263
- 終了ページ
- 267
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1111/ejh.12234
- 出版者・発行元
- WILEY-BLACKWELL
In addition to BCR, various rare fusion partners for the ABL1 gene have been reported in leukemia. We have identified the fusion gene SNX2-ABL1 in a pediatric case of acute lymphoblastic leukemia (ALL), which has only once previously been reported in an adult patient. Cytogenetic analysis detected this fusion gene arising from a t(5;9)(q22;q34) translocation. ALL cells carrying a SNX2-ABL1 fusion exhibited a BCR-ABL1+ ALL-like gene expression profile. The patient poorly responded to dasatinib but partially responded to imatinib. Treatment using tyrosine kinase inhibitors requires further investigation to optimize the genotype-based treatment stratification for patients with SNX2-ABL1 fusion.
- リンク情報
- ID情報
-
- DOI : 10.1111/ejh.12234
- ISSN : 0902-4441
- eISSN : 1600-0609
- PubMed ID : 24215620
- Web of Science ID : WOS:000331458500012